Previous Close | 0.2900 |
Open | 0.2974 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.2281 - 0.2975 |
52 Week Range | 0.2060 - 14.2200 |
Volume | |
Avg. Volume | 3,061,842 |
Market Cap | 2.597M |
Beta (5Y Monthly) | 1.07 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -14.4300 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The trial's primary goal is to assess the efficacy, safety and tolerability of daily oral doses of SCI-110 in adults aged 18 to 65 years.
FDA confirms that SciSparc’s study may proceed only a month after application submission TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that the U.S. Food and Drug Administration (“FDA”) has confirmed that its investigational new drug (“IND”) application for its first